Ainos (AIMD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AIMD Ainos

Watchlist

0.7400
+0.0116+1.59%

Trading Jul 23 10:19 ET

5.67MMarket Cap-224P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
Benzinga08:38 ET
12 Health Care Stocks Moving In Thursday's Intraday Session
BenzingaJul 4 12:31 ET
Market Mover | Ainos Shares Soar 30% After the Company Reports Progress in Clinical Trials of Ainos Flora Testing Device
moomoo NewsJun 14 09:40 ET · Movers
Ainos AIMD AI Ainos Flora Leverage; Bio-Path BPTH Phase 2 Data
BioPharmCatalystJun 14 08:25 ET
Express News | Ainos Inc - Clinical Trials for AI Nose-Powered Ainos Flora Device Moves Forward With 75Meaningful Case Results
ReutersJun 14 08:09 ET
Express News | Ainos Inc - Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by Nvidia Cuda
ReutersJun 14 08:09 ET

Comments

carlton griffiths

Jul 15 09:26

$Ainos(AIMD.US)$ hmm 👁 0.55

Stock Region

Jun 17 12:25

Diversified Healthcare Company Reveals Clinical Trial Advancements of Its AI-Powered Technology

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA.
Ainos, Inc. (NASDAQ: AIMD, AIMDW), a diversified healthcare company focusing on novel AI-powered point-of-care testing (POCT) and VELDONA low-dose interferon therapeutics, has recently announced advancements in the clinical trials of its "Ainos Flora" device. This volatile organic compound (VOC) PO...